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Abstract
Background: Successful scale-up of antiretroviral therapy (ART) during pregnancy has minimized infant HIV
acquisition, and over 1 million infants are born HIV-exposed but uninfected (HEU), with an increasing proportion
also exposed in utero to maternal ART. While benefits of ART in pregnancy outweigh risks, some studies have
reported associations between in utero ART exposure and impaired fetal growth, highlighting the need to identify
the safest ART regimens for use in pregnancy.
Methods: We compared birth anthropometrics of infants who were HEU with those HIV-unexposed (HU) in Cape
Town, South Africa. Pregnant women had gestational age assessed by ultrasound at enrolment. Women living with
HIV were on ART (predominately tenofovir-emtricitabine-efavirenz) either prior to conception or initiated during
pregnancy. Birth weights and lengths were converted to weight-for-age (WAZ) and length-for-age (LAZ) z-scores
using Intergrowth-21st software. Linear regression was used to compare mean z-scores adjusting for maternal and
pregnancy characteristics.
Results: Among 888 infants, 49% (n = 431) were HEU and 51% (n = 457) HU. Of 431 HEU infants, 62% (n = 268) were
exposed to HIV and antiretrovirals (ARVs) from conception and 38% (n = 163) were exposed to ARVs during
gestation but after conception (median fetal ARV exposure of 21 weeks [IQR; 17–26]). In univariable analysis, infants
who were HEU had lower mean WAZ compared with HU [β = − 0.15 (95% Confidence Interval (CI): − 0.28, − 0.020)].
After adjustment for maternal age, gravidity, alcohol use, marital and employment status the effect remained
[adjusted β − 0.14 (95%CI: − 0.28, − 0.01]. Similar differences were noted for mean LAZ in univariable [β − 0.20
(95%CI: − 0.42, − 0.01] but not multivariable analyses [adjusted β − 0.18 (95%CI: − 0.41, + 0.04] after adjusting for the
same variables. Mean WAZ and LAZ did not vary by in utero ARV exposure duration among infants who were HEU.
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Conclusion: In a cohort with high prevalence of ART exposure in pregnancy, infants who were HEU had lower
birth WAZ compared with those HU. Studies designed to identify the mechanisms and clinical significance of these
disparities, and to establish the safest ART for use in pregnancy are urgently needed.
Keywords: HIV-exposed uninfected, HIV-unexposed uninfected, Antiretroviral therapy, Weight-for-age, Length-for-
age
Background
Over 1 million women living with HIV (WLHIV) give
birth annually [1]. Successful scale-up of maternal anti-
retroviral treatment (ART) use in pregnancy has dramat-
ically reduced infant HIV acquisition but has resulted in
a large and expanding population of infants born HIV-
uninfected despite in utero exposure to HIV (HIV ex-
posed uninfected [HEU]) [2]. Several studies have shown
that infants who are HEU experience poorer growth,
health and survival outcomes compared with their coun-
terparts, infants who are HIV-unexposed (HU) [2–7].
Some studies have shown that fetal growth, measured by
an infant’s birth weight and length may be affected by in
utero antiretroviral (ARV) exposure [6, 8–10]. Many
studies demonstrated that in utero fetal exposure to HIV
and ARVs is associated with adverse birth outcomes
such as preterm birth, low birthweight and small-for
gestational age [11–15]. As the HIV epidemic has ma-
tured, the type of ART recommended for use in preg-
nancy, as well as the proportion of women on ART prior
to conception has changed. Identifying the safest ART
regimens for use in pregnancy that optimize maternal
and child outcomes represents a key public health chal-
lenge. Locations with generalized HIV epidemics and
high disease burden may be best positioned to provide
answers.
South Africa’s antenatal HIV prevalence is one of the
highest globally, reported at approximately 30% in 2017
[16]. In this high prevalence setting, more than 95% of
pregnant WLHIV receive ART in pregnancy, resulting in
the majority of infants who are HEU having exposure to
both the HIV virus and ARVs. It is difficult to disentan-
gle the extent to which observed disparities fetal growth
or birth outcomes reflect consequences of fetal exposure
to HIV or ARVs [2, 17]. However, it is clear that to
study adverse events associated with exposure to HIV
and ARVs separately, requires separate distinct meth-
odological approaches. To evaluate the effect of HIV ex-
posure specifically, a comparator group is needed of
similarly situated mother-infant pairs where women are
not living with HIV or receiving any ARVs in pregnancy.
To evaluate the effect of ARV exposure specifically, tim-
ing and duration of fetal exposure must be studied
among infants born to WLHIV. We used prospectively
collected data from the B Positive cohort study of infants
who are HEU and HU to evaluate associations between
in utero exposure to HIV/ART and infant birth an-
thropometrics, controlling for socio-economic differ-
ences. The primary aim of the parent study, the B
Positive study, was to monitor the effectiveness, impact
and risks of the World Health Organization’s (WHO’s)
Option B+ prevention of mother-to-child transmission
(PMTCT) of HIV strategy. In this secondary current
analysis of B Positive study data, the aim was to evaluate
associations between in utero exposure to HIV/ART and
infant birth weight-for-age and length-for-age z-scores,
as well as birth outcomes of preterm birth, low birth-
weight and small for gestational age.
Methods
Study setting
The B Positive study was a prospective observational
study conducted at a large primary healthcare facility in
Gugulethu, a peri urban township in Cape Town, South
Africa. The facility serves a population of about 350,000
with an estimated antenatal HIV prevalence of 30% [18].
Study design and study participants
Consecutive pregnant women > 18 years of age were re-
cruited into the study at their first antenatal care (ANC)
visit, regardless of HIV status. Study enrolment occurred
between January 2017 to July 2018. Women were eligible
for this study if they planned to reside in Cape Town
with their infants and had a confirmed maternal HIV
status at time of study enrolment. For women not
known to be living with HIV, a rapid antibody test was
used to confirm their HIV status which is standard of
care in routine ANC.
Study procedure
All eligible pregnant women who were able to provide
informed written consent were enrolled. Women were
followed antenatally for one to three study visits depend-
ing on the gestational age (GA) at enrolment. GA was
assessed by a dedicated study ultra-sonographer and re-
peated at all subsequent antenatal visits. Mother-infant
pairs were evaluated postnatally at 7 days and birth an-
thropometrics were abstracted as recorded at birth in
South Africa’s child Road to Health Booklet (RTHB).
Birth weight of new-borns was measured within 24 h of
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birth by health facility nurses. To be included in this sec-
ondary analysis, a woman had to deliver liveborn, single-
ton infant and birth weight and/or length data had to be
available on the child’s RTHB.
Data collection
Data collected included maternal demographics, preg-
nancy history and healthcare information. Question-
naires were administered to all women by trained study
interviewers. Pregnant women with a negative HIV test
at enrolment based on routine rapid antibody test, had
repeat HIV testing up to once every 3 months during
the antenatal period and immediately after delivery, as
per South Africa’s ANC standard guidelines [19]. For the
study, maternal HIV status and testing results were self-
reported and confirmed through medical chart review.
Per study protocol, all infants were weighed by study
staff after removal of clothing and diapers at the 7-days
postnatal study visit. Two measurements of infant
weight and length were taken at each visit by study staff.
Additional medical information was abstracted from
antenatal, obstetric, medical and laboratory records in-
cluding birth weight and length. Study data were col-
lected and managed using Research Electronic Data
Capture (REDCap) which is a secure, web-based applica-
tion designed to support data capture for research stud-
ies [20]. REDCap tool is hosted at the University of Cape
Town.
Exposures and outcomes
For this analysis, we used data collected during the ante-
natal study visits, at birth and 7 days after delivery/birth.
We evaluated two primary exposures of interest. The
first was exposure to HIV in utero (HEU versus HU),
while the second focused on timing of ARV exposure
only for infants who were HEU and consisted of a di-
chotomous variable of either ARV exposure from before
conception and during gestation; or after conception but
during gestation. Birth weight and length abstracted
from the RTHB were used to derive anthropometric pri-
mary outcomes, birth weight-for-age (WAZ) and length-
for-age (LAZ) z-scores, representing surrogate measures
of fetal growth. WAZ and LAZ scores were generated
using Intergrowth-21st software, which adjust for infant
GA at birth and infant sex [21]. Infant GA at delivery
was derived using the GA ascertained from a maternal
ultrasound done at enrolment, the date of enrolment
and the infant’s date of delivery. Potential confounders
identified for this analysis included maternal age, marital
status, gravidity and employment status (categorized as
formal or informal employment, attending school/col-
lege or unemployed). Alcohol use information was col-
lected using a published tool called AUDIT [22], and the
variable was a dichotomous variable (yes or no) for any
alcohol intake during pregnancy.
Statistical analysis
Data were analysed using Stata 14.0 (Stata Corporation,
College Station, TX, USA) [23]. Maternal and infant
characteristics were compared using Wilcoxon test, χ2
test or Fisher exact test as appropriate. Proportions of
secondary outcomes, preterm birth, low birthweight and
small-for-gestational age were compared by in utero
HIV exposure (HEU vs HU) and by timing of in utero
ARV exposure in HEU infants (before conception vs
after conception but during gestation). Univariable and
multivariable linear regression models were used to
compare the primary outcomes, mean WAZ and LAZ
scores first by in utero HIV exposure status, then by
timing of in utero ARV exposure in infants who were
HEU. All covariates in univariable analyses with a p-
value of 0.10 were included in multivariable analyses.
Additionally, an a priori decision was made to include
maternal age in the multivariable model, regardless of
univariable p-value.
Ethical considerations
This study was approved by the University of Cape
Town’s Faculty of Health Sciences Research Ethics Com-
mittee (UCT-HREC) and all women participating in the
study provided informed written consent for their own
participation and that of their infant’s.
Results
Out of 989 women enrolled in the B Positive cohort, 888
mother-infant pairs with live singleton births with birth
anthropometry data available were included in this ana-
lysis (Fig. 1). Of the 888 infants, 431 (49%) were HEU,
while 457 (51%) were HU. For maternal characteristics,
WLHIV were older [31 years; IQR 26–35] than women
living without HIV [27 years; IQR 23–32 (p < 0.001)];
more likely to be multigravid (3 pregnancies; [IQR 2–3]
versus 2 pregnancies; [IQR 2–3 (p < 0.001)]) and for-
mally employed (37% vs 31%; p < 0.001). (Table 1). Of
the 431 HEU infants, 268 (62%) were exposed to both
HIV and ARV from conception with median gestation of
39 weeks (IQR 38–40), while the remaining 163 (38%)
were exposed to ARV after conception but during gesta-
tion with median duration of fetal ART exposure of 21
weeks (IQR 17–26). Women who were already on ART
at conception were older ([32 years; IQR 29–36] versus
[28 years; IQR 25–33 (p < 0.001)]) and more likely to be
multigravid [3 pregnancies; IQR 2–4] than women who
initiated ART during pregnancy [2 pregnancies; IQR 2–3
(p < 0.001)]. There were no differences between WLHIV
and women without HIV with respect to gestational age
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at delivery, parity, maternal education, marital status and
alcohol use during pregnancy.
Infants who were HEU (both male and female) had
lower birth weight, [3.1 kg; IQR 2.8–3.4] and [3.1 kg;
IQR 2.7–3.3] compared to infants who were HU, [3.2 kg;
IQR 2.9–3.5] and [3.2 kg; IQR 2.9–3.4] (p = 18 and p =
0.004) respectively (Table 1). In univariable analysis
(Table 2), mean WAZ was lower among infants who
were HEU compared with infants who were HU [β = −
0.15 (95% Confidence Interval (CI): − 0.28, − 0.02), p =
0.02]. After adjusting for maternal age, gravidity, alcohol
use, marital and employment status, mean WAZ at birth
remained significantly lower for infants who were HEU
compared to those who were HU [adjusted β − 0.14
(95%CI: − 0.28, − 0.01), p = 0.04]. Similar differences
were noted for mean LAZ comparison with univariable
linear regression analysis [β − 0.20 (95%CI: − 0.42, −
0.02), p = 0.04]. However, in the multivariable analysis,
there was no significant mean LAZ difference [β − 0.18
(95%CI: − 0.41, + 0.04), p = 0.11] after adjusting for the
same variables.
When we restricted the population to HEU infants
only (Table 3), WAZ and LAZ for HEU infants exposed
to ARVs after conception were not different to infants
exposed to ARVs from conception.
There were no significant differences between WLHIV
and women without HIV with respect to gestational age
at delivery, parity, maternal education, marital status and
alcohol use during pregnancy. Preterm birth, low birth-
weight and small-for-gestational age were similar among
WLHIV compared to women living without HIV.
Discussion
In this prospective cohort of pregnant women seeking
ANC at a public health care facility in a peri-urban
township in South Africa, we found that infants who
were HEU experienced lower mean WAZ and LAZ at
birth compared to infants who were HU (Tables 1 and
2). Furthermore, among the infants who were HEU,
mean WAZ and LAZ did not vary by timing of ARV ex-
posure, either from before conception or initiated later
in gestation.
Our finding of lower WAZ at birth among infants who
were HEU is consistent with several studies in African
populations [2, 3, 6, 8]. While some studies were con-
ducted prior to universal maternal ART, others are simi-
lar to our cohort with lower WAZ noted in WLHIV
who receive ART. Similarly, LAZ was lower in infants
who were HEU, but the difference was attenuated after
adjusting for measured confounders. Our LAZ findings
approximate that from other studies done in African
populations [2, 3, 6]. The lack of a significant difference
could be due to limited statistical power to detect a lar-
ger effect. Our study is in the era of universal ART in
pregnancy and uniquely includes a group of women who
initiated ART prior to conception. Although there are
Fig. 1 Study flow diagram of participants
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Table 1 Characteristics of women and new-borns by infant HIV exposure and infant ART exposure
Women and infants by HIV
exposure status (N = 888)
WLHIV and HEU infants by













Age (years), median (IQR) 29 (25–33) 27 (23–32) 31 (26–35) < 0.001 32 (29–36) 28 (25–33) < 0.001
GA at enrolment (weeks) median, (IQR) 19 (14–24) 20 (14–25) 19 (13–23) 0.05 19 (13–24) 17 (13–22) 0.01
GA at delivery (weeks), median (IQR) 39 (38–40) 39 (38–40) 39 (38–40) 0.11 39 (38–40) 39 (38–40) 0.80
ART during (median, IQR) – – 37 (24–39) 39 (38–40) 21 (17–26)
ART initiation
Preconception ART 268 (62) * – 268 (62)
Antenatal ART 163 (38) * – 163 (38)
Gravidity
Median (IQR) 3 (2–3) 2 (1–3) 3 (2–3) < 0.001 3 (2–4) 2 (2–3) < 0.001
Parity
Median (IQR) 2 (1–2) 2 (1–2) 2 (1–2) 0.10 2 (1–2) 1 (1–2) < 0.001
ANC visits in this pregnancy
1 191 (22) 108 (24) 83 (19) 0.27 50 (19) 33 (20) 0.61
2 171 (19) 84 (19) 87 (20) 58 (21) 29 (18)
3 526 (59) 265 (58) 261 (61) 160 (60) 101 (62)
Education level completed
Primary 43 (5) 16 (3) 27 (6) 0.03 20 (7) 7 (4) 0.25
Secondary 827 (93) 428 (94) 399 (93) 246 (92) 153 (94)
Tertiary (University) 18 (2) 13 (3) 5 (1) 2 (1) 3 (2)
Relationship with father of child
Married/Cohabiting 392 (44) 199 (44) 193 (45) 0.71 133 (50) 60 (37) 0.01
Not married/ Non-cohabiting 496 (56) 258 (56) 238 (55) 135 (50) 103 (63)
Employment status
Formal employment 301 (34) 141 (31) 160 (37) 0.001 101 (38) 59 (36) 0.73
Informal employment 4 (1) 3 (1) 1 (1) 1 (1) 0 (0)
Attending school/college 67 (8) 50 (11) 17 (4) 9 (3) 8 (5)
Unemployed 516 (58) 263 (57) 253 (58) 157 (59) 96 (59)
Alcohol use in pregnancy
Yes 87 (10) 44 (10) 43 (10) 0.86 25 (9) 18 (11) 0.56
No 801 (90) 413 (90) 388 (90) 243 (90) 145 (89)
New-born characteristics
Infant Sex
Male 431 (49) 228 (50) 203 (47) 0.4 131 (49) 72 (44) 0.34
Female 457 (51) 229 (50) 228 (53) 137 (51) 91 (56)
Preterm delivery 101 (11) 47 (10) 48 (13) 0.29 32 (12) 22 (13) 0.63
Birth weight (median, IQR)
Male 3.2 (2.8–3.5) 3.2 (2.9–3.5) 3.1 (2.8–3.4) 0.18 3.2 (2.8–3.4) 3.1 (2.8–3.4) 0.43
Female 3.1 (2.8–3.4) 3.2 (2.9–3.4) 3.1 (2.7–3.3) 0.004 3.1 (2.8–3.4) 3.1 (2.6–3.3) 0.58
Birth length (median, IQR)
Male 50 (48–52) 50 (49–52) 50 (48–52) 0.21 50 (48–52) 50 (48–52) 0.93
Female 50 (48–52) 50 (48–52) 50 (48–51) 0.01 50 (48–52) 49 (47–51) 0.16
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overwhelming benefits of universal ART for both the
mother and the infant, it is critical that short- and long-
term potential risks be systematically studied using
sound methodological approaches, so that the safest reg-
imens for use in pregnancy are identified. The B Positive
study presents an optimal study design, as mother-infant
pairs were enrolled from the same community with simi-
lar socio-behavioural and socio-economic conditions. In
our analysis, we included only liveborn singleton infants.
This excludes stillbirths who often have intrauterine
growth restrictions as a result of placenta insufficiency
potential due to HIV and or ARVs [10], and neonatal
deaths. It is plausible that higher maternal HIV viral load
could influence placental development during preg-
nancy. A study from Botswana found that some ART
regimens may lead to placental insufficiency due to im-
paired endothelial function [10]. A forthcoming study on
pregnancy and birth outcomes is critical to identify the
effect of in utero fetal exposure to ARVs.
When we restricted our analysis to infants who were
HEU, focusing on in utero fetal exposure to ART, there
was no difference in anthropometric birth measures by
timing of an infant’s exposure, either prior to conception
or sometime after conception but during gestation. This
is consistent with findings from a study of infants who
were HEU in Brazil [24]. Unfortunately, a stratified ana-
lysis by ARV drug class was not practical, as most of the
women in our study sample (80%), were on a first line
efavirenz-based (EFV) regimen. Studies that can be
stratified by ARV drug class are urgently needed to es-
tablish the safest ARV drugs for use in pregnancy and
breastfeeding period [25, 26]. In analyzing anthropomet-
rics of infants who were HEU, we were unpowered to
evaluate outcomes by gestational duration of ARV ex-
posure, and therefore derived a dichotomous variable.
However, understanding if there is a “dose response” be-
tween in utero ARV exposure and birth anthropometrics
also represent a priority research area.
Our study had several strengths. The study had a com-
parator group of infants who were HU from the same
community, with common socio-behavioural and eco-
nomic characteristics between infants who were HEU
and those who were HU. Another strength was use of a
robust gestational age estimates by antenatal ultrasound.
We used Intergrowth-21st New-born Standards to gen-
erate WAZ and LAZ which adjusts for gestational age
and infant sex [21]. In the sub-group of infants who
were HEU, we had information on timing of ARV expos-
ure. Our study also has some limitations. Single site data
from a peri-urban South Africa community might not be
generalizable to other settings like rural areas with dif-
ferent backgrounds. Secondly, we were unable to dem-
onstrate causal effects due to potential unmeasured
confounders, always a concern in observational research.
However, the study and analytic approach were designed
to minimize confounding.
Table 1 Characteristics of women and new-borns by infant HIV exposure and infant ART exposure (Continued)
Women and infants by HIV
exposure status (N = 888)
WLHIV and HEU infants by












Low birthweight < 2500 g 95 (11) 45 (10) 50 (12) 0.39 31 (11) 19 (12) 0.97
Small for GA < 10th centile 98 (11) 50 (11) 48 (11) 0.92 32 (12) 16 (10) 0.40
Birth z-score, mean (SD)
Weight-for-age 888 0.08 (1.05) − 0.07 (0.99) 0.03 −0.05 (1.02) − 0.10 (0.94) 0.65
Length-for-age 864 0.82 (1.70) 0.61 (1.58) 0.07 0.65 (1.626) 0.55 (1.53) 0.53
IQR Interquartile range, SD Standard deviation, n Number of participants, GA Gestational age, ANC Antenatal clinic
HEU HIV-exposed uninfected, HU HIV-unexposed, ART Antiretroviral therapy
* P-value from chi-square or Fisher’s exact test, comparison between HU and HEU
**P-value from chi-square or Fisher’s exact test, comparison in HEU between preconception ART and antenatal ART
Table 2 Univariable and Multivariable Linear regression for comparison of WAZ and LAZ between HEU and HU infants
Anthropometric measure Univariable Multivariable
Predictor N β (95% CI) P-value β (95% CI) P-value
Weight for age Z-score (WAZ) HU 457 Ref Ref
HEU 431 −0.15 (−0.28; − 0.02) 0.02 − 0.14 (− 0.28; − 0.01) 0.04
Length for age Z-score (LAZ) HU 420 Ref
HEU 400 −0.20 (− 0.42; − 0.01) 0.04 − 0.18 (− 0.41; + 0.04) 0.11
Adjusted for maternal age, gravidity, alcohol use, marital and employment status,
HEU HIV-exposed uninfected, HU HIV-unexposed
β: mean change in z-score between HEU and HU, CI Confidence interval, N Number of participants
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Conclusion
Despite universal ART treatment during pregnancy and
breastfeeding, which has improved maternal health and
significantly reduced infant HIV acquisition, fetal growth
remains impaired for infants with exposed to in utero
HIV/ART compared to infants born to mothers without
HIV. Studies to identify clinical significance of growth
disparities between HEU infants and HU infants are ur-
gently needed as well as establishing the safest ARV drug
for use in pregnancy.
Abbreviations
ANC: Antenatal clinic; ARV: Antiretroviral; ART: Antiretroviral therapy;
GA: Gestational age; HEU: HIV-exposed uninfected; HU: HIV-unexposed;
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mother-to-child transmission; WAZ: Weight-for-age z-score; WLHIV: Women
living with HIV; SD: standard deviation
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